Clinical Utilization of Newly Approved Oncology Medications
Clinical Utilization of Newly Approved Oncology Medications in Middle Eastern Population
The efficacy and safety of different medications vary from one individual to another and from one ethnic group to another. Therefore, strong interest in the study of pharmacogenomic and pharmacoepidemiology has evolved recently.
There are multiple examples of oncology drugs being more effective in certain ethnic population compared to other. For example, irinotecan combined with cisplatin was very effective drug in the management of small cell lung cancer in the Japanese patients while an identical study done in the US revealed no major benefit to this combination in American population
Studienübersicht
Detaillierte Beschreibung
Another example is having more benefit drawn from tyrosine kinase inhibitors (Erlotinib or Gefitinib) in Asian patients.
Immunotherapy is a new class of cancer treatment that works to harness the innate powers of the immune system to fight cancer. Because of the immune system's unique properties, these therapies may hold greater potential than current treatment approaches to fight cancer more powerfully, to offer longer-term protection against the disease, to come with fewer side effects, and to benefit more patients with more cancer types
Immunotherapy includes treatments that work in different ways. Some boost the body's immune system in a very general way. Others help train the immune system to attack cancer cells specifically. Immunotherapy has become an important part of treating some types of cancer. Newer types of immune treatments are now being studied, and they'll impact how we treat cancer in the future.
Recently, multiple immunotherapy treatment been approved with a couple of EGFR resistant medications.
Many new oncology drugs are being used in Middle Eastern countries including Saudi Arabia for different indications without being studied in the Middle Eastern population. These medications' efficacy and safety profiles may differ from those patients studied for drug development and approval due to difference in population's characteristics.
The goal of this study is to observe, summarize and report the patterns of the use of these drugs and describe their efficacy and safety profile in the early phases of their use.
The investigators aim is to build on the existing experience and knowledge by utilization of classic methodology and approaches on a larger scale and more effective way to paint picture of the performance of a certain therapy in the real life world. The use of prospective design will help evaluate the efficacy and safety of therapies already used in practice, generate new hypothesis, and/or determine the outcome of certain diseases.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
-
Riyadh, Saudi-Arabien, 11426
- Rekrutierung
- King Abdul Aziz Medical City for National Guard Health Affairs
-
Kontakt:
- Oncology Research
- Telefonnummer: 14601 0096612520088
- E-Mail: oncologyresearch@ngha.med.sa
-
Kontakt:
- Abdularahman Jazieh, MD,MPH
- Telefonnummer: 14688 0096612520088
- E-Mail: jazieha@ngha.med.sa
-
Riyadh, Saudi-Arabien
- Rekrutierung
- King Abdul Aziz Medical City for National Guard
-
Kontakt:
- Nagham RZ Sheblaq
- Telefonnummer: 53352 009668011111
- E-Mail: sheblaqn@ngha.med.sa
-
Kontakt:
- Telefonnummer: 53352 009668011111
- E-Mail: sheblaqn@ngha.med.sa
-
Hauptermittler:
- Nagham RZ Sheblaq, BS.c
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- All patients with cancer or hematological malignancies receiving new oncology medications (defined as a medication in the first five years of their introduction to the ME market
- Patient accepts to participate in study and signing consent form
Exclusion Criteria:
- None
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Descriptive measures of the pattern of use of the new medications in our population
Zeitfenster: 3 years
|
3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Measuring the efficacy in terms of response
Zeitfenster: 3 years
|
3 years
|
|
Measuring the efficacy in terms of progression-free survival (PFS)
Zeitfenster: 3 years
|
3 years
|
|
Measuring the efficacy in terms of overall survival (OS)
Zeitfenster: 3 years
|
3 years
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- RC15/097/R
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .